.Pharmacolibrary.Drugs.ATC.N.N02CA01_1

Information

Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.

Pharmacokinetics

Pharmacokinetic parameters estimated for nasal spray administration in healthy adults.

References

1. Lipton, RB, et al., & Albrecht, D (2025). Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review. Headache 65(3) 527–535. DOI:10.1111/head.14877 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39601088

2. Shrewsbury, SB, et al., & Hoekman, J (2019). STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD. Headache 59(3) 394–409. DOI:10.1111/head.13476 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30659611

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)